A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 1, Pages e83884
Publisher
Public Library of Science (PLoS)
Online
2014-01-04
DOI
10.1371/journal.pone.0083884
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis
- (2014) S. Bertholet et al. JOURNAL OF IMMUNOLOGY
- MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
- (2013) Mark T. Orr et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The next 10 years for tuberculosis vaccines: do we have the right plans in place?
- (2013) Joel Meyer et al. Expert Review of Vaccines
- Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
- (2013) Mark T. Orr et al. JOURNAL OF CONTROLLED RELEASE
- Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
- (2012) Colleen Olive Expert Review of Vaccines
- Potent Induction of Antibody-Secreting B Cells by Human Dermal-Derived CD14+ Dendritic Cells Triggered by Dual TLR Ligation
- (2012) K. Matthews et al. JOURNAL OF IMMUNOLOGY
- The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine
- (2012) S. L. Baldwin et al. JOURNAL OF IMMUNOLOGY
- Humanized TLR4/MD-2 Mice Reveal LPS Recognition Differentially Impacts Susceptibility to Yersinia pestis and Salmonella enterica
- (2012) Adeline M. Hajjar et al. PLoS Pathogens
- Innate Immune Recognition ofMycobacterium tuberculosis
- (2011) Johanneke Kleinnijenhuis et al. Clinical & Developmental Immunology
- Tuberculosis vaccines in clinical trials
- (2011) Rosalind Rowland et al. Expert Review of Vaccines
- Programming the magnitude and persistence of antibody responses with innate immunity
- (2011) Sudhir Pai Kasturi et al. NATURE
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
- (2011) Rhea N. Coler et al. PLoS One
- Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells
- (2011) Steven C. Derrick et al. VACCINE
- Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns
- (2010) Benjamin M. N. Kagina et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
- (2010) G. Schreibelt et al. BLOOD
- Use of defined TLR ligands as adjuvants within human vaccines
- (2010) Malcolm S. Duthie et al. IMMUNOLOGICAL REVIEWS
- Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice
- (2010) Qing Zhu et al. JOURNAL OF CLINICAL INVESTIGATION
- Applying TLR Synergy in Immunotherapy: Implications in Cutaneous Leishmaniasis
- (2010) V. S. Raman et al. JOURNAL OF IMMUNOLOGY
- Dual Stimulation of MyD88‐Dependent Toll‐Like Receptors Induces Synergistically Enhanced Production of Inflammatory Cytokines in Murine Bone Marrow–Derived Dendritic Cells
- (2010) Daniel Mitchell et al. JOURNAL OF INFECTIOUS DISEASES
- Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy
- (2010) Mathias Krummen et al. JOURNAL OF LEUKOCYTE BIOLOGY
- A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
- (2010) Rhea N. Coler et al. PLoS One
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
- (2010) S. Bertholet et al. Science Translational Medicine
- Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
- (2009) Tino F. Schwarz ADVANCES IN THERAPY
- Cell-Mediated Immune Responses in Tuberculosis
- (2009) Andrea M. Cooper Annual Review of Immunology
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
- (2009) A. M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
- Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells
- (2009) S. M. Makela et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tracking epitope-specific T cells
- (2009) James J Moon et al. Nature Protocols
- Modulation of adaptive immunity with Toll-like receptors
- (2009) Santhakumar Manicassamy et al. SEMINARS IN IMMUNOLOGY
- Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines
- (2008) Q. Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started